Secondly, there is growing interest in targeting metabolic signaling pathways, including PI3K/AKT/mTOR, AMPK, and HIF-1α, as a therapeutic approach to disrupt the metabolic dependencies of ocular tumors. This evidence concerns the gene AKT1 and eye neoplasm.